April 2019

Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC Gets Expansion

April 10, 2019


The FDA expanded the indication for for pemetrexed (Alimta) injection plus pembrolizumab (Keytruda) and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK alterations.

FDA Advises Against Starting Olaratumab for Soft Tissue Sarcoma

April 09, 2019

Clinical Trials in Progress

The FDA recommends that no new patients with advanced soft tissue sarcoma (STS) be treated with olaratumab (Lartruvo) plus doxorubicin, following the negative results of the phase III ANNOUNCE trial.

Nurses Must Adapt to Meet the Needs of a Diverse Patient Population

April 07, 2019

Partner Perspectives

Rapid changes occurring nationally and worldwide—including shifts in demographics, languages, epidemiological patterns, and social systems— have direct implications for patient care. These trends are projected to continue, and nurses need to be prepared to care for increasingly diverse patient populations.

Nurses Must Keep Up With Cancer Care's Constant Change

April 04, 2019

From the Chairman

Because nurses bridge the gap between advocate and provider, they are in the perfect position to recognize patients’ needs and seek solutions for those undergoing radiation therapy.